We examined the association between alcohol consumption, adherence and viral load (VL) in a cohort of 940 alcohol-consuming, human immunodeficiency virus (HIV)-positive men receiving antiretroviral therapy in Mumbai. Some of the participants (16.7%) had missed >1 doses in the last four days and 17.6% reported >1 treatment interruptions in the last 12 months; 60.8% of the participants consumed alcohol >2 times/month, 62.8% consumed >3 drinks/typical day and 11.5% reported binge drinking >1 times/month; 76.4% of the participants had VL<200 copies/mL. Higher alcohol consumption was associated with nonadherence (odds ratio [OR]: 1.21; 95% confidence interval [CI]: 1.11–1.31) and treatment interruptions (OR: 1.20; 95% CI: 1.11–1.31). We found no association between alcohol use and VL. There was, however, a significant interaction effect of alcohol use and nonadherence on virological failure (Adjusted Odds Ratio [AOR]: 1.23; 95% CI: 1.03–1.47) implying that alcohol negatively impacts VL outcomes but mediated through adherence. Alcohol use was associated with poor adherence, which in turn was a strong predictor of virological failure.
NACO. National AIDS control organization. Part B.
Delhi, India:
Ministry of Family Health and Welfare, 2014–2015.
3.
SchensulJSinghSGuptaK, et al.
Alcohol and HIV in India: a review of current research and intervention. AIDS Behav2010;
2010: S1–S7.
4.
NaikECasanasBPazareA, et al.
Cost of treatment: The single biggest obstacle to HIV/AIDS treatment adherence in lower-middle class patients in Mumbai, India. Indian J Sex Transm Dis AIDS2009;
30(1); 23–27. 2009 Jan;30
5.
SchensulSHaTSchensulJ, et al.
The role of alcohol on antiretroviral therapy adherence among persons living with HIV in urban India. J Stud Alcohol Drugs2017;
78: 716–724.
6.
YathirajABUnnikrishnanBRamapuramJ, et al.
Factors influencing adherence to antiretroviral therapy among people living with HIV in coastal south India. J Int Assoc Provid AIDS Care2016;
15: 529–533.
7.
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Res Hum Retroviruses2000;
16: 1123–1133.
8.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services, www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 2 November 2017).
9.
MurrayJElashoffMIacono-ConnorsL, et al.
The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS1999;
13: 797–804.
10.
MarschnerICollierACoombsR, et al.
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis1998;
177: 40–47.
11.
ThiébautRMorlatPJacqmin-GaddaH, et al.
Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d’Epidémiologie du SIDA en Aquitaine (GECSA). AIDS2000;
14: 971–978.
12.
CohenMChenYMcCauleyM, et al.
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med2011;
365: 493–505.
13.
HavlirDBassettRLevitanD, et al.
Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA2001;
286: 171–179. 2001 Jul 11
14.
NettlesRKiefferTKwonP, et al.
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA2005;
293: 817–829.
15.
MurrayJZaundersJKoelschK, et al.
Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting. AIDS Res Hum Retroviruses2013;
29: 1621–1625.
16.
World Health Organization. Consolidated guidelines on the useof antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach.
Geneva:
World Health Organization, 2013.
17.
RibaudoHLennoxJCurrierJ, et al. Virologic failure endpoint definition in clinical trials: Is using HIV-1 RNA threshold <200 copies/mL better than <50 copies/mL? An analysis of ACTG studies. In: 16th Conference on retroviruses and opportunistic infections, 8–11 2009, Montreal, Canada.
18.
KarlssonAYoungerSMartinJN, et al.
Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS2004;
18: 981–989.
19.
AlemanSSoderbargKVisco-ComandiniU, et al.
Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS2002;
16: 1039–1044.
20.
PatersonDSwindellsSMohrJ, et al.
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med2000;
133: 21–30.
21.
RosenblumMDeeksSLaanMVD, et al.
The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One2009;
4: e7196
22.
BangsbergD.Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis2006; 43: 939--941.
23.
BezabheWChalmersLBereznickiL, et al.
Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore)2016;
95: e3361.
24.
SherrLLampeFNorwoodS, et al.
Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care2008;
20: 442–448.
25.
RenjuJMoshabelaMMcLeanE, et al.
Side effects’ are ‘central effects’ that challenge retention in HIV treatment programmes in six sub-Saharan African countries: a multicountry qualitative study. Sex Transm Infect2017;
93: e052971.
26.
SafrenSBielloKSmeatonL, et al.
Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One2014;
9: e104178.
27.
UthmanOMagidsonJSafrenS, et al.
Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. Curr HIV/AIDS Rep2014;
11: 291–307.
28.
WastiSSimkhadaPRandallJ, et al.
Barriers to and facilitators of antiretroviral therapy adherence in Nepal: a qualitative study. J Health Popul Nutr2012;
30: 410–419.
29.
HeestermansTBrowneJAitkenS, et al.
Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. BMJ Glob Health2016;
1: e000125.
30.
SametJPhillipsSHortonN, et al.
Detecting alcohol problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum Retroviruses2004;
20: 151–155.
31.
KrupitskyEHortonNWilliamsE, et al.
Alcohol use and HIV risk behaviors among HIV-infected hospitalized patients in St. Petersburg, Russia. Drug Alcohol Depend2005;
79: 251–256.
32.
GrossRBellamySRatshaaB, et al.
Effects of sex and alcohol use on antiretroviral therapy outcomes in Botswana: a cohort study. Addiction2017;
112: 73–81.
33.
HendershotCStonerSPantaloneD, et al.
Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr2009;
52: 180–202.
34.
ConenAWangQGlassT, et al.
Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr2013;
64: 472–478.
35.
JusticeAMcGinnisKTateJ, et al.
Risk of mortality and physiologic injury evident with lower alcohol exposure among HIV infected compared with uninfected men. Drug Alcohol Depend2016;
161: 95–103.
36.
KahlerCLiuTCioeP, et al.
Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. AIDS Behav2017;
21: 1825–1835.
37.
ChanBPradeepAPrasadL, et al.
Prevalence and correlates of psychosocial conditions among people living with HIV in southern India. AIDS Care2017;
29: 746–750.
38.
KahlerCLiuTCioeP, et al.
Direct and indirect effects of heavy alcohol use on clinical outcomes in a longitudinal study of HIV patients on ART. AIDS Behav 2017; 21: 1825--1835.
39.
BaumMRafieCLaiS, et al.
Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses2010;
26: 511–518.
40.
WanderaBTumwesigyeNNankabirwaJ, et al.
Hazardous alcohol consumption is not associated with CD4+ T-cell count decline among PLHIV in Kampala Uganda: A prospective cohort study. PLoS One2017; 12(6): e0180015.
41.
KalichmanKGreblerTAmaralC, et al.
Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med2014;
21: 811–820.
42.
SametJChengDLibmanH, et al.
Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr2007;
46: 194–199.
43.
WHO. The alcohol use disorders identification test. 2nd ed.Geneva:
WHO, 2001.
BrooksR and The EuroQol Group.The current state of play. Health Pol1996;
37: 53.
46.
RadloffL.The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas1997;
1: 385–401.
47.
MillerVSabinCHertogsK, et al.
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS2000;
14: 2857–2867.
48.
LuebbertJTweyaHPhiriS, et al.
Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Clin Infect Dis2012;
55: 441–448.
